EUVIMEDEUVIMED entdecken
Crossref

Bronchopulmonary Dysplasia in the First Year: Insights Into Severity, Medication Use, and Healthcare Utilization

Eliaz Brumer iD, Veronika Shabanova, Haley Urbach iD, Angela Montgomery, Matthew Grossman, Laura Chen iD, Pnina Weiss iD, Sarah Kandil iD

Pediatric Pulmonology · 2025-08 · 60 (8)

DOI: 10.1002/ppul.71254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 26.08.2025. Verfasst von Eliaz Brumer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Section of Pulmonary, Allergy-Immunology, and Sleep Medicine, Yale University, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Dexamethasone, Patient Acceptance of Health Care. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Bronchopulmonary dysplasia (BPD) is a chronic lung disease affecting premature infants. This study aimed to (1) examine associations between BPD severity and respiratory outcomes and healthcare utilization; (2) evaluate the impact of outpatient pediatric pulmonology follow‐up; and (3) assess whether dexamethasone administration during NICU stay influences postdischarge respiratory morbidity.

Methods

This retrospective cohort study included 161 infants diagnosed with BPD (2021–2023) using the 2019 BPD severity classification. Key outcomes included the prevalence of prescriptions for albuterol, inhaled corticosteroid, and systemic steroids, as well as ED visits and admission within the first‐year postdischarge. The study analyzed associations between dexamethasone use during NICU admission, outpatient pulmonology follow‐ups, and respiratory morbidity.

Results

Of 161 infants, 32.9% had grade‐1, 59.0% grade‐2, and 8.1% grade‐3 BPD. Dexamethasone administration during NICU admission increased with BPD severity ( p < 0.001). Pediatric pulmonology follow‐up was common in grade‐2 (77.9%) and grade‐3 (84.6%) but lower in grade‐1 (47.2%, p < 0.001). Use of inhaled medications and systemic steroids varied significantly by severity. Nearly half of the cohort (47.2%) had a hospital visit for respiratory issues postdischarge, and 22.3% required hospitalization.

Conclusion

This study characterizes respiratory outcomes and healthcare utilization in infants with BPD during the first‐year post‐NICU discharge. While morbidity and healthcare utilization increased with BPD severity, nearly half of the entire cohort required hospital visits, underscoring a significant disease burden even among infants with milder disease. These findings highlight the importance of structured longitudinal follow‐up across all BPD severity levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchopulmonary DysplasiaDexamethasonePatient Acceptance of Health CareHumansRetrospective StudiesMaleFemaleInfant, NewbornSeverity of Illness IndexInfantIntensive Care Units, NeonatalInfant, PrematureAlbuterolBronchodilator AgentsGlucocorticoidsHospitalization

Stichwörter der Autor:innen

bronchopulmonary dysplasiapediatric pulmonologyprematurity

Substanzen

DexamethasoneAlbuterolBronchodilator AgentsGlucocorticoids

Autor:innen und Institutionen

  • Department of Pediatrics, Section of Pulmonary, Allergy-Immunology, and Sleep Medicine, Yale University, New Haven, Connecticut, USA.
  • Department of Pediatrics, Section of General Pediatrics, Yale University, New Haven, Connecticut, USA.
  • Department of Biostatistics, Yale University, New Haven, Connecticut, USA.
  • Department of Pediatrics, Section of Neonatal-Perinatal Medicine, Yale University, New Haven, Connecticut, USA.
  • Department of Pediatrics, Section of Critical Care Medicine, Yale University, New Haven, Connecticut, USA.

ORCID-Profile: Eliaz Brumer, Haley Urbach, Laura Chen, Pnina Weiss, Sarah Kandil

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Brumer, E., Shabanova, V., Urbach, H., Montgomery, A., Grossman, M., Chen, L., Weiss, P., & Kandil, S. (2025). Bronchopulmonary Dysplasia in the First Year: Insights Into Severity, Medication Use, and Healthcare Utilization. Pediatric Pulmonology, 60(8). https://doi.org/10.1002/ppul.71254

Vancouver

Brumer E, Shabanova V, Urbach H, Montgomery A, Grossman M, Chen L, et al. Bronchopulmonary Dysplasia in the First Year: Insights Into Severity, Medication Use, and Healthcare Utilization. Pediatric Pulmonology. 2025;60(8). doi:10.1002/ppul.71254

BibTeX
@article{Brumer2025,
  author = {Brumer, Eliaz and Shabanova, Veronika and Urbach, Haley and Montgomery, Angela and Grossman, Matthew and Chen, Laura and Weiss, Pnina and Kandil, Sarah},
  title = {Bronchopulmonary Dysplasia in the First Year: Insights Into Severity, Medication Use, and Healthcare Utilization},
  journal = {Pediatric Pulmonology},
  year = {2025},
  volume = {60},
  number = {8},
  doi = {10.1002/ppul.71254}
}
Kostenlos starten →